Q2 EPS Estimates for HealthEquity Lifted by Zacks Research

HealthEquity, Inc. (NASDAQ:HQY - Free Report) - Investment analysts at Zacks Research raised their Q2 2026 earnings per share estimates for shares of HealthEquity in a report issued on Tuesday, June 24th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.70 for the quarter, up from their previous estimate of $0.68. The consensus estimate for HealthEquity's current full-year earnings is $2.32 per share. Zacks Research also issued estimates for HealthEquity's Q3 2026 earnings at $0.73 EPS, Q4 2026 earnings at $0.76 EPS, FY2026 earnings at $3.05 EPS, Q1 2027 earnings at $0.81 EPS, Q4 2027 earnings at $0.96 EPS, FY2027 earnings at $3.59 EPS, Q1 2028 earnings at $0.99 EPS and FY2028 earnings at $4.18 EPS.

A number of other brokerages have also recently commented on HQY. Raymond James Financial raised HealthEquity from an "outperform" rating to a "strong-buy" rating and dropped their price target for the company from $120.00 to $115.00 in a research report on Tuesday, March 25th. KeyCorp cut their target price on shares of HealthEquity from $110.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. The Goldman Sachs Group boosted their price target on shares of HealthEquity from $94.00 to $104.00 and gave the company a "neutral" rating in a research report on Wednesday, June 4th. JMP Securities upped their price target on shares of HealthEquity from $110.00 to $117.00 and gave the company a "market outperform" rating in a research note on Wednesday, June 4th. Finally, Barrington Research lifted their price objective on shares of HealthEquity from $112.00 to $125.00 and gave the company an "outperform" rating in a research note on Thursday, June 5th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, HealthEquity presently has a consensus rating of "Buy" and a consensus target price of $118.09.

HealthEquity Stock Up 0.9%

HQY opened at $104.86 on Friday. HealthEquity has a twelve month low of $65.01 and a twelve month high of $116.65. The company's 50-day moving average price is $97.61 and its two-hundred day moving average price is $97.93. The stock has a market cap of $9.07 billion, a price-to-earnings ratio of 76.54, a PEG ratio of 1.59 and a beta of 0.49. The company has a quick ratio of 4.06, a current ratio of 4.06 and a debt-to-equity ratio of 0.50.

HealthEquity (NASDAQ:HQY - Get Free Report) last posted its earnings results on Tuesday, June 3rd. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.81 by $0.16. The firm had revenue of $330.80 million for the quarter, compared to analysts' expectations of $322.25 million. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. During the same quarter last year, the firm earned $0.80 EPS.

Institutional Trading of HealthEquity

Institutional investors have recently made changes to their positions in the stock. Transce3nd LLC bought a new stake in shares of HealthEquity in the fourth quarter worth about $29,000. WPG Advisers LLC purchased a new stake in HealthEquity in the 1st quarter worth approximately $28,000. Versant Capital Management Inc purchased a new stake in HealthEquity in the 1st quarter worth approximately $28,000. Smartleaf Asset Management LLC grew its position in shares of HealthEquity by 34.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 384 shares of the company's stock worth $37,000 after buying an additional 98 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ grew its position in shares of HealthEquity by 1,934.8% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 468 shares of the company's stock worth $45,000 after buying an additional 445 shares during the last quarter. Hedge funds and other institutional investors own 99.55% of the company's stock.

Insider Activity at HealthEquity

In related news, EVP Elimelech Rosner sold 58,000 shares of the stock in a transaction on Friday, June 6th. The shares were sold at an average price of $112.56, for a total transaction of $6,528,480.00. Following the transaction, the executive vice president now owns 75,689 shares of the company's stock, valued at approximately $8,519,553.84. This trade represents a 43.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Henry Fiore sold 8,881 shares of the firm's stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $78.26, for a total value of $695,027.06. Following the transaction, the executive vice president now directly owns 56,655 shares in the company, valued at $4,433,820.30. This trade represents a 13.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 304,581 shares of company stock valued at $33,664,018 over the last three months. 1.50% of the stock is owned by corporate insiders.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.